Vi K. Chiu

3.3k total citations · 2 hit papers
27 papers, 2.7k citations indexed

About

Vi K. Chiu is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Vi K. Chiu has authored 27 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Vi K. Chiu's work include Colorectal Cancer Treatments and Studies (5 papers), Economic and Financial Impacts of Cancer (5 papers) and Cellular transport and secretion (4 papers). Vi K. Chiu is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Economic and Financial Impacts of Cancer (5 papers) and Cellular transport and secretion (4 papers). Vi K. Chiu collaborates with scholars based in United States, China and Czechia. Vi K. Chiu's co-authors include Mark R. Philips, Trever G. Bivona, Edwin Choy, David Michaelson, Adrienne D. Cox, Heidi H. Wiener, Takashi Morimoto, Ivan E. Ivanov, Ian M. Ahearn and Angela Hach and has published in prestigious journals such as Nature, Cell and Journal of Biological Chemistry.

In The Last Decade

Vi K. Chiu

26 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Endomembrane Trafficking of Ras

1999 624 citations Edwin Choy, Vi K. Chiu et al. Cell profile →
Ras signalling on the endoplasmic reticulum and the Golgi

2002 516 citations Vi K. Chiu, Trever G. Bivona et al. Nature Cell Biology profile →

Peers

Countries citing papers authored by Vi K. Chiu

Since Specialization

Citations

This map shows the geographic impact of Vi K. Chiu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vi K. Chiu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vi K. Chiu more than expected).

Fields of papers citing papers by Vi K. Chiu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vi K. Chiu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vi K. Chiu. The network helps show where Vi K. Chiu may publish in the future.

Co-authorship network of co-authors of Vi K. Chiu

This figure shows the co-authorship network connecting the top 25 collaborators of Vi K. Chiu. A scholar is included among the top collaborators of Vi K. Chiu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vi K. Chiu. Vi K. Chiu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The PRL3-zumab paradigm: A multicenter, single-dose-level phase 2 basket clinical trial design of an unconventional cancer immunotherapy 2025 ·Cell Reports Medicine ·Jae‐Hyun Park, Min Thura, Vi K. Chiu, (unknown), (unknown), (unknown), (unknown), (unknown), Jie Li, Ke Zhang, Wei Zheng, Matthew Chau Hsien Ng, Qi Zeng	1
2	DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish 2024 ·Journal of Clinical Oncology ·Samuel J. Klempner, Mohamad Bassam Sonbol, Zev A. Wainberg, Hope E. Uronis, Vi K. Chiu, Aaron J. Scott, (unknown), Mohamedtaki Abdulaziz Tejani, Vincent Chung, (unknown), (unknown), Ying Zhang, Michael H. Kagey, Jason Baum, Cynthia A. Sirard, Rachel A. Altura, Jaffer A. Ajani	12
3	Talazoparib (Tala) in patients (pts) with colorectal cancer (CRC) with BRCA1/2 mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. 2024 ·Journal of Clinical Oncology ·Kathleen J. Yost, Michael Rothe, Pam K. Mangat, Elizabeth Garrett‐Mayer, (unknown), Eugene R. Ahn, Timothy Lewis Cannon, Vi K. Chiu, Maged Khalil, Brian Kim, (unknown), (unknown), (unknown), Dominique C. Hinshaw, Susan Halabi, Richard L. Schilsky	1
4	Abstract 5181: Early activity and biomarker evaluation of NT219 in combination with cetuximab in a Phase 1/2 study of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) 2024 ·Cancer Research ·Ari J. Rosenberg, Shumei Kato, Daniel Johnson, Aron Popovtzer, Vi K. Chiu, Ravit Geva, Hava Ben‐David, Tomer Meirson, Michael Schickler, Hadas Reuveni	0
5	System-wide approach on biosimilars adoption in oncology: Strategic plan on switching and cost savings. 2023 ·Journal of Clinical Oncology ·(unknown), Kyung Kim, (unknown), Edwin M. Posadas, Kevin S. Scher, (unknown), Vi K. Chiu, Márcio A. Diniz, André Rogatko, (unknown), (unknown), (unknown), Vipul Patel, Robert A. Figlin, Rita Shane, Karen L. Reckamp	1
6	Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. 2023 ·Journal of Clinical Oncology ·Timothy Lewis Cannon, Michael Rothe, Elizabeth Garrett‐Mayer, Vi K. Chiu, Jimmy J. Hwang, Namrata Vijayvergia, Olatunji B. Alese, Elie G. Dib, (unknown), Kelsey Klute, Vaibhav Sahai, Eugene R. Ahn, Deepti Behl, (unknown), Ramya Thota, Walter J. Urba, Eddy S. Yang, (unknown), Susan Halabi, Richard L. Schilsky	2
7	Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study 2022 ·Clinical Colorectal Cancer ·Manish A. Shah, Takayuki Yoshino, Niall C. Tebbutt, Axel Grothey, Josep Tabernero, Rui‐Hua Xu, Andrés Cervantes, Sang Cheul Oh, Kensei Yamaguchi, Marwan Fakih, Alfredo Falcone, Christina Wu, Vi K. Chiu, Jiří Tomášek, Johanna C. Bendell, (unknown), Matthew Hitron, Bo Xu, Julien Taı̈eb, Eric Van Cutsem	22
8	Correlates of poor adherence to a healthy lifestyle among a diverse group of colorectal cancer survivors 2019 ·Cancer Causes & Control ·Cindy K. Blair, Jean A. McDougall, Vi K. Chiu, Charles L. Wiggins, Ashwani Rajput, Elizabeth Harding, Anita Y. Kinney	14
9	Socioeconomic disparities in health-related quality of life among colorectal cancer survivors 2019 ·Journal of Cancer Survivorship ·Jean A. McDougall, Cindy K. Blair, Charles L. Wiggins, (unknown), Vi K. Chiu, Ashwani Rajput, Anita Y. Kinney	38
10	Abstract C52: Disparities in treatment-related financial hardship and adherence to surveillance colonoscopy guidelines in ethnically, linguistically, and geographically diverse colorectal cancer survivors 2018 ·Cancer Epidemiology Biomarkers & Prevention ·Jean A. McDougall, Matthew P. Banegas, Charles L. Wiggins, Ashwani Rajput, Vi K. Chiu, Kristina G. Flores, Anita Y. Kinney	1
11	Actionable genomic biomarkers in a low socioeconomic status (SES) population with gastrointestinal (GI) cancers. 2018 ·Journal of Clinical Oncology ·Vi K. Chiu, Diaa Osman, Jessica Belmonte, (unknown), Heloisa P. Soares, David Martin, Joshua A. Hanson, (unknown), Anita Y. Kinney, Mohammad A. Vasef, (unknown)	1
12	The prognostic significance of CXCL1 hypersecretion by human colorectal cancer epithelia and myofibroblasts 2015 ·Journal of Translational Medicine ·(unknown), Thang Kien Chiu, Michael Fara, Jinru Shia, Zhaoshi Zeng, Martin R. Weiser, Philip B. Paty, Vi K. Chiu	45
13	Identification and characterization of RET fusions in advanced colorectal cancer 2015 ·Oncotarget ·(unknown), Samuel J. Klempner, Christopher R. Garrett, Tara Elisabeth Seery, Eric M. Sanford, Sohail Balasubramanian, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller, Siraj M. Ali, Vi K. Chiu	80
14	Angiocrine factors from Akt-activated endothelial cells balance self-renewal and differentiation of haematopoietic stem cells 2010 ·Nature Cell Biology ·Hideki Kobayashi, Jason M. Butler, Rebekah K. O’Donnell, Mariko Kobayashi, Bi‐Sen Ding, Bryant Bonner, Vi K. Chiu, Daniel J. Nolan, Koji Shido, Laura E. Benjamin, Shahin Rafii	293
15	PostprenylationCAAXProcessing Is Required for Proper Localization of Ras but Not Rho GTPases 2005 ·Molecular Biology of the Cell ·David Michaelson, (unknown), Vi K. Chiu, Martin O. Bergö, (unknown), (unknown), Stephen G. Young, Mark R. Philips	123
16	Carboxyl Methylation of Ras Regulates Membrane Targeting and Effector Engagement 2004 ·Journal of Biological Chemistry ·Vi K. Chiu, (unknown), (unknown), Heidi H. Wiener, (unknown), (unknown), Mark R. Philips, Michael H. Pillinger	41
17	Phospholipase Cγ activates Ras on the Golgi apparatus by means of RasGRP1 2003 ·Nature ·Trever G. Bivona, Ignacío Pérez de Castro, Ian M. Ahearn, Theresa M. Grana, Vi K. Chiu, Peter J. Lockyer, Peter J. Cullen, Àngel Pellicer, Adrienne D. Cox, Mark R. Philips	357
18	Ras signalling on the endoplasmic reticulum and the Golgi breakdown → 2002 ·Nature Cell Biology ·Vi K. Chiu, Trever G. Bivona, Angela Hach, J. Bernard Sajous, (unknown), Heidi H. Wiener, Ronald L. Johnson, Adrienne D. Cox, Mark R. Philips	516
19	Endomembrane Trafficking of Ras breakdown → 1999 ·Cell ·Edwin Choy, Vi K. Chiu, (unknown), (unknown), Takashi Morimoto, David Michaelson, Ivan E. Ivanov, Mark R. Philips	624
20	Mammalian Prenylcysteine Carboxyl Methyltransferase Is in the Endoplasmic Reticulum 1998 ·Journal of Biological Chemistry ·Qun Dai, Edwin Choy, Vi K. Chiu, Julia D. Romano, Sandra R. Slivka, (unknown), Susan Michaelis, Mark R. Philips	248

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact